CXCL8 and neoplasm: Finally, serum IL-8 levels were significantly (p < 0.05) decreased after SU5416, bevacizumab and celecoxib, whereas its tumour levels were diminished (p < 0.05) after VEGF and SU5416 and significantly increased (p < 0.05) after celecoxib.